Montelukast Mabo (Montelukast)

Montelukast works by selectively binding to the cysteinyl leukotriene receptor CysLT1, blocking the action of leukotriene D4 and related mediators. This inhibition prevents bronchoconstriction, reduces vascular permeability, and limits the recruitment of inflammatory cells in the respiratory tract, thereby improving airflow and decreasing allergic inflammation. The effect is achieved with once‑daily oral dosing.

The appropriate dose of Montelukast Mabo is determined by the prescribing clinician based on the patient’s age, weight, severity of disease, and overall health status. Dosage recommendations differ for asthma maintenance, allergic rhinitis, and exercise‑induced bronchoconstriction, and the medication should be taken exactly as instructed on the prescription label.

The safety of montelukast in pregnancy has not been definitively established, and it is classified as a pregnancy category with limited data. Women who are pregnant or planning to become pregnant should discuss potential risks and benefits with their healthcare provider. Montelukast is excreted in breast milk, so nursing mothers should also seek medical advice before use.

To request Montelukast Mabo, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including any required temperature control—and assists with import documentation.

Montelukast belongs to a different therapeutic class than inhaled corticosteroids (ICS). While ICS directly suppress airway inflammation, montelukast blocks leukotriene‑mediated pathways and is often used as an add‑on therapy or for patients who cannot tolerate steroids. Clinical guidelines suggest montelukast may be less effective than high‑dose ICS for severe asthma, but it offers the convenience of oral administration and can improve control in certain phenotypes.

Montelukast Mabo should be stored at room temperature, preferably below 25 °C (77 °F). Keep the tablets in their original blister pack or container to protect them from moisture and light. Do not store in areas with high humidity or extreme heat, and keep out of reach of children. No refrigeration is required.

Montelukast is taken orally, usually as a tablet swallowed whole with water. The medication is typically taken once daily in the evening, but the exact timing and frequency are determined by the prescribing physician. Patients should follow the label instructions and not crush or chew the tablet unless specifically directed. Consistent daily use is important for optimal therapeutic effect.

Although generally well tolerated, montelukast carries a risk of serious adverse events. These include severe allergic reactions such as rash, urticaria, or angioedema, and neuropsychiatric effects like depression, anxiety, or suicidal thoughts. Rarely, hepatic injury or severe skin conditions such as Stevens‑Johnson syndrome may occur. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with a known hypersensitivity to the drug or any of its excipients. It should be used with caution in patients with existing liver disease, severe psychiatric disorders, or a history of serious allergic reactions. Pregnant or nursing women, as well as children under the approved age for specific indications, must only use the medication under direct medical supervision.